Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2

Conditions

Sarcoma, Kaposi 2HIV Infections 2Acquired Immunodeficiency Syndrome 2Lymphoma 1

Interventions

Doxorubicin 13Zidovudine 12Vincristine 11Bleomycin 8Cyclophosphamide 7Interferon alpha-2 6Etoposide 5Dexamethasone 5sargramostim 4Specimen Handling 4Methotrexate 4Magnetic Resonance Spectroscopy 4Leucovorin 4Filgrastim 4Cytarabine 4Rituximab 3Prednisone 3Nivolumab 3interferon alfa-n1 2cabozantinib 2Thalidomide 2Isotretinoin 2Interleukin-2 2Fluorouracil 2Didanosine 2Bortezomib 2Biopsy 2Allopurinol 2prednylidene 1pembrolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × HIV Infections × Didanosine × Clear all
NCT00001114 2021-11-01

The Safety and Effectiveness of Interferon Alfa-2B Plus Didanosine in Patients With Kaposi's Sarcoma

National Institute of Allergy and Infectious Diseases (NIAID)

Phase 2 Completed
90 enrolled
Sarcoma

Acquired Immunodeficiency Syndrome, Sarcoma, Kaposi, HIV Infections

NCT00000954 2021-10-29

A Study of Chemotherapy Plus ddI or ddC in the Treatment of AIDS-Related Kaposi's Sarcoma

National Institute of Allergy and Infectious Diseases (NIAID)

Phase 1 Completed
72 enrolled
Sarcoma

Acquired Immunodeficiency Syndrome, Sarcoma, Kaposi, HIV Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡